Search

This study used accelerometers and hydrophones to measure the vibration and underwater noise from two different types of offshore wind turbine installed near the East China Sea Bridge (Shanghai). Wind speed and rotor speed were also monitored synchronously. The spectrograms of the vibration and underwater noise signals display well-defined spectral lines that are easily distinguishable. Line-component spectra of both vibration and underwater noise signals were synchronously extracted through filtering and correlation analysis. On this basis, relationships between the intensity and frequency of wind turbine vibration and underwater noise line-component spectra, rotor speed, and wind speed were analyzed. Results indicate that rotor speed is positively correlated with wind speed, and that the peak vibration frequencies and intensities of both types of turbine are positively correlated with rotor speed. Consequently, it can be concluded that the frequency and intensity of turbine-generated underwater noise are closely related to wind speed. Additionally, the vibration mechanism and the characterization of underwater noise of the wind turbines have been revealed. [ABSTRACT FROM AUTHOR]

Background: The role of liver stiffness measurements (LSM) in patients with primary biliary cholangitis (PBC) remains to be further elucidated. Aims: To clarify the prognostic role of LSM and to validate the "novel concepts" proposed by the Baveno VII Working Group. Methods: An analysis of the prognostic significance of LSM was performed involving 672 patients. Results: LSM and ΔLSM/ΔT were independent risk factors for liver decompensation, liver transplantation, or liver-related death (primary outcomes, p < 0.001, both). A rule of 5 kPa for LSM (10–15–20 kPa) could be used to denote progressively higher relative risks of primary outcomes. Patients with LSM < 10 kPa have a negligible 3-year risk of primary outcomes (< 1%). Cut-off values of 10 and 15 kPa can be used to classify PBC patients into low-, medium-, and high-risk groups. A clinically significant decrease in LSM, evaluated at 6, 12, or 24 months elastography tests, was associated with a substantially reduced risk of primary outcomes (p < 0.05, all), which can be defined as a decrease in LSM of > − 20% associated with LSM < 20 kPa or any decrease to LSM < 10 kPa. A clinically significant increase in LSM, evaluated at 6, 12, or 24 months elastography tests, was associated with a substantially raised risk of primary outcomes (p < 0.05, all), which can be defined as an increase in LSM of ≥ + 20% or any increase to LSM ≥ 15 kPa. Conclusions: LSM can be used to monitor disease progression and predict long-term prognosis in patients with PBC. [ABSTRACT FROM AUTHOR]

Although CD19-specific chimeric antigen receptor (CAR) T cells are curative for patients with relapsed or refractory large B-cell lymphoma (R/R LBCL), disease relapse with tumor antigen-positive remains a challenge. Cytokine/chemokine-expressing CAR-T cells could overcome a suppressive milieu, but the clinical safety and efficacy of this CAR-T therapy remain unclear. Here we report the preclinical development of CD19-specific CAR-T cells capable of expressing interleukin (IL)-7 and chemokine (C-C motif) ligand (CCL)-19 upon CD19 engagement (referred to as 7 × 19 CAR-T cells) and results from a phase 1 and expansion phase trial of 7 × 19 CAR-T cell therapy in patients with R/R LBCL (NCT03258047). In dose-escalation phase, there were no dose-limiting toxicities observed. 39 patients with R/R LBCL received 7 × 19 CAR-T with doses ranged from 0.5 × 106–4.0 × 106 cells per kg body weight. Grade 3 cytokine release syndrome occurred in 5 (12.8%) patients and ≥ grade 3 neurotoxicity in 4 (10.3%) patients. The overall response rate at 3 months post-single infusion was 79.5% (complete remission, 56.4%; partial response, 23.1%). With a median follow-up of 32 months, the median progression-free survival was 13 months, and median overall survival was not reached, with an estimated rate of 53.8% (95% CI, 40.3% to 72.0%) at two years. Together, these long-term follow-up data from the multicenter clinical study suggest that 7 × 19 CAR-T cells can induce durable responses with a median overall survival of greater than 2 years, and have a manageable safety profile in patients with R/R LBCL. [ABSTRACT FROM AUTHOR]